Ensatinib

PreclinicalSmall molecule

PPeking University Cancer Hospital & Institute

Ensatinib is one of 35 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Lenvima

Eisai

Preclinical

6 3

Ofev

Boehringer Ingelheim

Preclinical

7 4

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 5

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

REGN2810

1 7

Vidaza

Bristol-Myers Squibb

Preclinical

1 8

Treatment

GSK

Preclinical

1 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT05186506

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Not yet recruiting·SSichuan University·Phase 2·NCT05186506·152 enrolled

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

Unknown status·PPeking University Cancer Hospital & Institute··NCT05132218·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ensatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ensatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ensatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking University Cancer Hospital & Institute

Ensatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

References

Drug Info

Quick Facts

Related News